

INTRODUCTION TO ICH GOOD CLINICAL PRACTICE

Dr. Win Aung

MBBS, MMedSc, FACTM, FRCP

Deputy Director General (Retd.), DMR

Member, Institutional Review Board, DMR

13 Feb 2020

DMR

INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE (ICH)

Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects.

INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL
REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE (ICH)

ICH HARMONISED GUIDELINE

INTEGRATED ADDENDUM TO ICH E6(R1):
GUIDELINE FOR GOOD CLINICAL PRACTICE

E6(R2)

Current Step 4 version

dated 9 November 2016

The guideline was developed with consideration of the current good clinical practices of the European Union, Japan, and the United States, as well as those of Australia, Canada, the Nordic countries and the World Health Organization (WHO).

The **objective** of this ICH GCP Guideline is to provide a unified standard for the European Union (EU), Japan and the United States to facilitate the mutual acceptance of clinical data by the regulatory authorities in these jurisdictions.

ICH Good Clinical Practice



Historical Background

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) , formerly the International Conference on Harmonisation (ICH) , was established in 1990 .

- is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration.

ICH MISSION

“ To achieve greater harmonisation worldwide to ensure that safe, effective, and high quality medicines are developed and registered in the most resource-efficient manner ”

Harmonisation is achieved through the development of ICH Guidelines via a process of scientific consensus with regulatory and industry experts working side-by-side. Key to the success of this process is the commitment of the ICH regulators to implement the final Guidelines.

The International Council for Harmonisation (ICH), held the inaugural Assembly meetings on **23 October 2015** establishing ICH as an international association, a non-profit legal entity under Swiss law.

Since its announcement of organisational changes, ICH has grown as an organisation and now includes 16 Members and 32 Observers.

ICH

INTERNATIONAL COUNCIL FOR HARMONISATION of Technical Requirements for Pharmaceuticals for Human Use

- Unique harmonisation initiative for regulators and pharmaceutical industry
- Originally founded in 1990
- Reformed as a non-profit legal entity under Swiss Law on 23 October 2015

Purpose of ICH

Promotion of public health through **international harmonisation** that contributes to:

- Prevention of unnecessary duplication of clinical trials and post market clinical evaluations
- Development and manufacturing of new medicines
- Registration and supervision of new medicines
- Reduction of unnecessary animal testing without compromising safety and effectiveness

Accomplished through **Technical Guidelines** that are implemented by the regulatory authorities.

Members:

- Founding Regulatory:
 - EC, Europe; MHLW/PMDA, Japan; FDA, US
- Founding Industry:
 - EFPIA; JPMA; PhRMA
- Standing Regulatory:
 - Swissmedic, Switzerland; Health Canada, Canada
- Regulatory:
 - ANVISA, Brazil; CFDA, China; HSA, Singapore; MFDS, Republic of Korea; TFDA, Chinese Taipei
- Industry:
 - IGBA; WSMI; BIO



See <http://www.ich.org/about/members-observers.html> for details

ICH Products (as of June 2018)

- Over 60 Guidelines on technical requirements

Q

uality

S

afety

E

fficacy

M

ultidisciplinary

- Electronic Standards for the Transfer of Regulatory Information (ESTRI, E2B)
- Consideration documents (e.g. participation of women in clinical trials)



See <http://www.ich.org/products/guidelines.html> for details

E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)**

**March 2018
Procedural**

**OMB Control No. 0910-0843 Expiration Date 09/30/2020
See additional PRA statement in section 9 of this guidance.**

INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL
REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE (ICH)

ICH HARMONISED GUIDELINE

**INTEGRATED ADDENDUM TO ICH E6(R1):
GUIDELINE FOR GOOD CLINICAL PRACTICE**

E6(R2)

Current Step 4 version
dated 9 November 2016

GLOSSARY

Good Clinical Practice (GCP)

A standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected.

Clinical Trial / Study

Any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to study absorption, distribution, metabolism, and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy. The terms clinical trial and clinical study are synonymous.

Investigational Product

A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use.

Investigator

A person responsible for the conduct of the clinical trial at a trial site. If a trial is conducted by a team of individuals at a trial site, the investigator is the responsible leader of the team and may be called the **principal investigator**.

Sub-investigator

Any individual member of the clinical trial team designated and supervised by the investigator at a trial site to perform critical trial-related procedures and/or to make important trial-related decisions.

Investigator's Brochure

A compilation of the clinical and nonclinical data on the investigational product(s) which is relevant to the study of the investigational product(s) in human subjects

INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL
REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE (ICH)

ICH HARMONISED GUIDELINE

**INTEGRATED ADDENDUM TO ICH E6(R1):
GUIDELINE FOR GOOD CLINICAL PRACTICE
E6(R2)**

Current Step 4 version
dated 9 November 2016

**INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR
GOOD CLINICAL PRACTICE ICH**

ICH Consensus Guideline

INTRODUCTION	1
1. GLOSSARY	3
2. THE PRINCIPLES OF ICH GCP	9
3. INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)	10
3.1 Responsibilities	10
3.2 Composition, Functions and Operations	11
3.3 Procedures	11
3.4 Records	12
4. INVESTIGATOR	13
4.1 Investigator's Qualifications and Agreements	13
4.2 Adequate Resources	13
4.3 Medical Care of Trial Subjects	14
4.4 Communication with IRB/IEC	14
4.5 Compliance with Protocol	14
4.6 Investigational Product(s)	15
4.7 Randomization Procedures and Unblinding	15
4.8 Informed Consent of Trial Subjects	16
4.9 Records and Reports	19
4.10 Progress Reports	19
4.11 Safety Reporting	20
4.12 Premature Termination or Suspension of a Trial	20
4.13 Final Report(s) by Investigator	20
5. SPONSOR	21
5.0 Quality Management	21
5.1 Quality Assurance and Quality Control	22
5.2 Contract Research Organization (CRO)	22
5.3 Medical Expertise	23

of Safety	36
.....	37
to Source Data/Documents	37
and Quality Assurance	37
.....	37
ing and Record Keeping	37
Insurance	37
Policy	37
.....	37
ATTORNEY BROCHURE SET	38
.....	38
Iterations	38
Title Page	38
Confidentiality Statement	39
An Investigator's Brochure	39
Table of Contents	39
Summary	39
Introduction	39
Physical, Chemical, and Pharmaceutical Properties and Formulation	39
Nonclinical Studies	39
Effects in Humans	41
Summary of Data and Guidance for the Investigator	42
1)	42
2)	44
1. DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL	45
.....	45
Initial Phase of the Trial Commences	46
Initial Conduct of the Trial	50
tion or Termination of the Trial	50

Safety	37
Source Data/Documents	37
and Quality Assurance	37
.....	37
and Record Keeping	37
Insurance	37
cy	37
.....	37
OR'S BROCHURE	38
.....	38
erations	38
e Page	38
Confidentiality Statement	39
Investigator's Brochure	39
le of Contents	39
nnary	39
duction	39
sical, Chemical, and Pharmaceutical Properties and Formulation	39
eclinical Studies	39
ects in Humans	41
nnary of Data and Guidance for the Investigator	42
.....	43
.....	44
OCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL	45
.....	45
ical Phase of the Trial Commences	46
ical Conduct of the Trial	55
ction or Termination of the Trial	59

A total of 8 titles

ICH HARMONISED GUIDELINE
INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR
GOOD CLINICAL PRACTICE ICH
E6(R2)

ICH Consensus Guideline

TABLE OF CONTENTS

INTRODUCTION.....	1
1. GLOSSARY	2
2. THE PRINCIPLES OF ICH GCP	9
3. INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)	10
3.1 Responsibilities.....	10
3.2 Composition, Functions and Operations	11
3.3 Procedures.....	11
3.4 Records.....	12
4. INVESTIGATOR.....	13

THE PRINCIPLES OF ICH GCP

- The principles of GCP are concerned with the safety, rights and wellbeing of participants and the validity and quality of the research data.
- This **guideline** should be followed when generating clinical trial data that are intended to be submitted to regulatory authorities.
- There are thirteen principles in the 2016 ICH-GCP guidelines

13 Key Principles of ICH GCP

Principle 1

Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with GCP and the applicable regulatory requirement(s).

The Declaration of Helsinki (1964)

The DoH was first adopted in the 1964 World Medical Association (WMA) General Assembly in Helsinki.

- “The well-being of the subject should take precedence over the interests of science and society”
- Consent should be in writing
- Use caution if participant is in dependent relationship with researcher
- Greater access to benefit

World Medical Association Declaration of Helsinki

Ethical Principles for Medical Research

Involving Human Subjects

World Medical Association

Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the:

- 29th WMA General Assembly, Tokyo, Japan, October 1975
- 35th WMA General Assembly, Venice, Italy, October 1983
- 41st WMA General Assembly, Hong Kong, September 1989
- 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996
- 52nd WMA General Assembly, Edinburgh, Scotland, October 2000
- 53rd WMA General Assembly, Washington, DC, USA, October 2002 (Note of Clarification added)
- 55th WMA General Assembly, Tokyo, Japan, October 2004 (Note of Clarification added)
- 59th WMA General Assembly, Seoul, Republic of Korea, October 2008
- 64th WMA General Assembly, Fortaleza, Brazil, October 2013

35 principles

Adopted at 18th WMA General Assembly in June 1964

Amended at 64th WMA General Assembly in Oct 2013

Published in JAMA in Nov 2013

Special Communication

World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects

World Medical Association

Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the
25th WMA General Assembly, Tokyo, Japan, October 1989
31st WMA General Assembly, Manila, July-October 1994
34th WMA General Assembly, Hong Kong, September 1997
38th WMA General Assembly, Geneva, May, Republic of South Africa, October 1998
42nd WMA General Assembly, Edinburgh, Scotland, October 2000
45th WMA General Assembly, Washington, DC, USA, October 2002 (Vote of Clarification added)
48th WMA General Assembly, Tokyo, Japan, October 2005 (Vote of Clarification added)
51st WMA General Assembly, Seoul, Republic of Korea, October 2008
54th WMA General Assembly, Barcelona, Spain, July-October 2011

Preamble

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data.

The Declaration is intended to be read as a whole and each of its constituent paragraphs should be applied with consideration of all other relevant paragraphs.

2. Consistent with the mandate of the WMA, the Declaration is addressed primarily to physicians. The WMA encourages others who are involved in medical research involving human subjects to adopt these principles.

General Principles

1. The Declaration of Geneva of the WMA binds the physician with the words, "The health of my patient will be my first consideration," and the International Code of Medical Ethics declares that, "A physician shall act in the patient's best interest when providing medical care."

2. It is the duty of the physician to promote and safeguard the health, wellbeing and rights of patients, including those who are involved in medical research. The physician's knowledge and conscience are dedicated to the fulfillment of this duty.

3. Medical progress is based on research that ultimately must be conducted on healthy individuals involving human subjects.

4. The primary purpose of medical research involving human subjects is to understand the causes, development and effects of diseases and improve prevention, diagnosis and the quality of treatment (prevention, procedures, and treatment). From the

level of patient interventions must be evaluated continually through research for their safety, effectiveness, efficiency, accessibility and quality.

5. Medical research on subjects has ethical standards that protect and ensure respect for all human subjects and protect their health and rights.

6. While the primary purpose of medical research is to generate new knowledge, this goal cannot take precedence over the rights and interests of individual research subjects.

7. It is the duty of physicians whose involvement in medical research is to protect the life, health, dignity, integrity, right to self-determining privacy, and confidentiality of personal information of research subjects. The responsibility for the protection of research subjects must always rest with the physician or other health care professionals and never with the research subjects, even though they have given consent.

8. Physicians must consider the ethical, legal and regulatory norms and standards for researching involving human subjects in their own countries as well as applicable international norms and standards. International international treaties, legal regulations or agreements should reduce or eliminate any of the protection for research subjects set forth in this Declaration.

9. Medical research should be conducted in a manner that minimizes possible harm to the environment.

10. Medical research involving human subjects must be conducted only by individuals with the appropriate ethics and scientific education, training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional.

Introduction & Objectives (Special Communication)

World Medical Association Declaration of Helsinki

11. Groups that are underrepresented in medical research should be provided appropriate access to participation in research.

12. Physicians who combine medical research with medical care should ensure that patients in research only do so to the extent that this is justified by its potential prevention, diagnosis or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

13. Appropriate compensation and treatment for subjects who are harmed as a result of participating in research must be ensured.

Risks, Burdens and Benefits

14. In medical practice and medical research, most interventions involve risks and burdens.

Medical research involving human subjects may only be conducted if the importance of the objective outweighs the risks and burdens to the research subjects.

15. All medical research involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and groups involved in the research to ensure patients will have no avoidable harm to them and neither individuals nor groups affected by the condition under investigation.

Measures to minimize the risks must be implemented. The risks must be continuously monitored, assessed and documented by the researchers.

16. Physicians may not be involved in a research study involving human subjects unless they are confident that the risks have been adequately assessed and/or can be satisfactorily managed.

When the risks are found to outweigh the potential benefits or when there is a cumulative proof of definite outcomes, physicians must assess whether to continue, modify or immediately stop the study.

Vulnerable Groups and Individuals

17. Some groups and individuals are particularly vulnerable and may have an increased risk of being susceptible to having an ethical harm.

All vulnerable groups and individuals should receive specially considered protection.

18. Medical research with a vulnerable group is only justified if the research is responsive to the health needs or priorities of this group and the research cannot be carried out in a non-vulnerable group. In addition, this group should stand to benefit from the knowledge, practices or interventions that result from the research.

Scientific Requirements and Research Values

19. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

20. The design and performance of each research study involving human subjects must be clearly described and justified in a research protocol.

The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsorship, institutional affiliation, potential conflicts of interest, incentives for subjects and information regarding provisions for treating and/or compensating subjects who are harmed as a consequence of participating in the research study.

In clinical trials, the protocol must also describe appropriate arrangements for post-trial care.

Research Ethics Committees

21. The research protocol must be submitted to the committee(s) responsible for the study design. This committee must be constituted before the study begins. This committee must be independent in its functioning, must be independent of the researchers, the sponsor and any other undue influence and must be fully qualified. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and standards but these must not be allowed to override or eliminate any of the protections for research subjects set forth in this Declaration.

The committee must have the right to monitor ongoing studies. The researchers must provide monitoring information to the committee, especially information about any serious adverse events. An amendment to the protocol may be made without committee approval and approval by the committee. After the end of the study, the researchers must submit a final report to the committee containing a summary of the study's findings and conclusions.

Privacy and Confidentiality

22. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information.

Informed Consent

23. Participation by individuals capable of giving informed consent as subjects in medical research must be voluntary. Although it

may be appropriate to consult family members or community leaders, no individual capable of giving informed consent may be enrolled in research study unless he or she freely agrees.

24. In medical research involving human subjects a qualified giving informed consent, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, past study procedures and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information.

After ensuring that the potential subject understands their formation, the physician or another appropriately qualified individual must then seek the potential subject's freely given informed consent, preferably in writing. If the consent cannot be expressed involving the same individual must be formally documented and witnessed.

Individual research subjects should be given the option of being informed about the general outcome and results of the study.

25. When varying informed consent for participation in a research study the physician must be particularly cautious if the potential subject is in a dependent relationship with the physician or may experience adverse health situations if the informed consent must be sought by an appropriately qualified individual who is completely independent of the relationship.

26. For a potential research subject who is incapable of giving her formal consent, the physician must seek informed consent from the legally authorized representative. These individuals must not be included in a research study that have no likelihood of benefit for them unless it is evident to the physician that the group represented by the potential subject, the research cannot be conducted for persons capable of providing for formal consent, and the research entails only minimal risk and minimal burden.

29. When a potential research subject who is deemed incapable of giving informed consent is able to give consent to decisions about participation in research, the physician must seek that consent in addition to the consent of the legally authorized representative. The potential subject's consent should be requested.

32. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is temporary and the nature of the research group, for such circumstances the physician must seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent post

vided that the specific measures for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by an ethics committee. Consent is considered if the research must be delayed or when a possible harm to the subject or a legally authorized representative.

33. The physician must fully inform the patient who is capable of their own study in the research. The ethical of a patient require the physician to study in the patient's decision to refuse to form the study must never adversely affect the patient-physician relationship.

34. For medical research involving identifiable human materials (e.g., such as research on material data contained in biobanks or similar repositories, physicians must seek informed consent for its collection, storage and use. There may be exceptional situations where consent would be impossible or impracticable to obtain for such research. In such situations, the researcher may then only after consultation and approval of a research ethics committee.

Use of Placebo

35. The benefits, risks, burdens and efforts of a research intervention must be tested against those of the best proven intervention, except in the following circumstances:

When no proven intervention exists, the use of placebo, or no intervention, is acceptable as

When the compelling and scientifically sound methodological reasons the use of any intervention less effective than the best proven one, the use of placebo, or no intervention is necessary to determine the efficacy or safety of an intervention

and the patients who receive any intervention less effective than the best proven one, placebo, or no intervention will not be subject to additional risks of serious or irreversible harm as a result of not receiving the best proven intervention.

Extreme care must be taken to avoid abuse of this option.

Post-Trial Provisions

36. In advance of conducting any research, researchers and their sponsoring governments should make provisions for post-trial access for subjects only who still need an intervention identified as being effective in the trial. This information must also be disclosed to subjects during the informed consent process.

Research Registration and Publication and Dissemination of Results

38. Every research study involving human subjects must be registered in a publicly accessible database after enrollment of the first subject.

39. Researchers, authors, sponsors, editors and publishers fulfill their ethical obligations with regard to the publication and dissemination of the results of research. Researchers have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. Editors should adhere to accepted guidelines for ethical reporting. Together authors, editors and publishers must be held accountable for the completeness and accuracy of their reports. Sources of funding, institutional affiliations and conflicts of interest must be declared in the publications. Reports of research must be consistent with the principles of this Declaration should not be accepted for publication.

Genetics Interventions in Clinical Practice

42. In the treatment of an individual patient, where genetic interventions do not exist or where known interventions have been ineffective, the physician, after seeking expert advice, with the informed consent from the patient or a legally authorized representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, preventing health or alleviating suffering. This intervention should undergo scrutiny by made the subject of research designed to evaluate its safety and efficacy. In all cases, prior information must be provided and, where appropriate, made publicly available.

Articles in Research Ethics

Responsible for the research study
Responsible for the research study
Responsible for the research study
Responsible for the research study
Responsible for the research study

Responsible for the research study
Responsible for the research study
Responsible for the research study
Responsible for the research study
Responsible for the research study

Responsible for the research study
Responsible for the research study
Responsible for the research study
Responsible for the research study
Responsible for the research study



Principle 2

Before a trial is initiated, foreseeable risks and inconveniences should be weighed against the anticipated benefit for the individual trial subject and society. A trial should be initiated and continued only if the anticipated benefits justify the risks.

Principle 3

The rights, safety and well-being of participants always take precedence over the interests of science and society.

Principle 4

The available nonclinical and clinical information on an investigational product should be adequate to support the proposed clinical trial.

Principle 5

Clinical trials should be scientifically sound, and described in a clear, detailed protocol.

Principle 6

A trial should be conducted in compliance with the protocol that has received prior institutional review board (IRB)/independent ethics committee (IEC) approval/favourable opinion.

Principle 7

The medical care given to, and medical decisions made on behalf of, subjects should always be the responsibility of a qualified physician or, when appropriate, of a qualified dentist.

Principle 8

Each individual involved in conducting a trial should be qualified by education, training, and experience to perform his or her respective task(s).

Principle 9

Freely given informed consent should be obtained from every subject prior to clinical trial participation.

-

Principle 10

All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation and verification.

This principle applies to all records referenced in this guideline, irrespective of the type of media used.

Principle 11

The confidentiality of records that could identify subjects should be protected, respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirement(s).

Principle 12

Investigational products should be manufactured, handled, and stored in accordance with applicable good manufacturing practice (GMP). They should be used in accordance with the approved protocol.

Principle 13

Systems with procedures that assure the quality of every aspect of the trial should be implemented.

Aspects of the trial that are essential to ensure human subject protection and reliability of trial results should be the focus of such system.

ICH E6(R2) Addendum

ICH E6(R1) has been amended to encourage implementation of improved and more efficient approaches to clinical trial design, conduct, oversight, recording, and reporting while continuing to ensure human subject protection and reliability of trial results

Compliance with this **standard** provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible.

Principles of ICH GCP (Summary)

Ethics:

1. Ethical conduct of clinical trials
2. Benefits justify risks
3. Rights, safety, and well-being of subjects prevail

Protocol and Science:

4. Nonclinical and clinical information supports the trial
5. Compliance with a scientifically sound, detailed protocol

Principles of ICH GCP (Summary)

Responsibilities:

6. IRB/IEC approval prior to initiation
7. Medical care/decisions by qualified physician
8. Each individual is qualified (education, training, experience) to perform his/her tasks

Informed Consent:

9. Freely given from every subject prior to participation

Principles of ICH GCP (Summary)

Data Quality and Integrity:

- 10. Accurate reporting, interpretation, and verification
- 11. Protects confidentiality of records

Investigational Products:

- 12. Conform to GMP's and used per protocol

Quality Control/Quality Assurance:

- 13. Systems with procedures to ensure quality of every aspect of the trial

ICH GCP TRAINING WORKSHOP

Training Workshop on “International Council for Harmonisation Good Clinical Practice (ICH-GCP) ” (13 - 14 Feb 2020)

General objective

- To strengthen good clinical research practice among clinicians at Medical and Health related Universities under MoHS

Specific objectives

- To promote awareness and understanding of the importance of good clinical practice among clinicians in research involving human subjects
- To encourage conduct of clinical research studies in Myanmar research culture
- To cultivate the application of GCP principles in clinical studies conducted in Myanmar

Expected outcomes

- The workshop will improve the clinician's understanding of the GCP principles, clinical research methods, common ethical problems in clinical research, and build the capacity of faculty in good clinical and research practice. Certificate of training will be provided.

- *This Training Workshop is intended primarily for faculty members and staff engaged in research including those supported by MoHS but is applicable to scholarly research in general*
- *It seeks to provide a practical overview of the rules, regulations, and professional practices that define the GCP*

- *The coverage in this training workshop is not exhaustive and leaves room for continued reading and discussion in the laboratory and classroom, at professional meetings, and in any other setting where faculty and researchers gather to discuss their work*

Conclusion

- We hope to encourage faculty, researchers and the academic and research institutions to make a special effort to understand, discuss, and teach others about the ICH-GCP
- This workshop should be seen as the beginning and not the end of learning about this important aspect of our professional life



- *“Coming together is a beginning. Keeping together is progress. Working together is success.”*

Henry Ford (July 30, 1863 – April 7, 1947)

- ICH official link and ICH GCP E6(R2) : Guideline for GCP document
- <https://ich.org/page/efficacy-guidelines>>
- ICH GCP online training,.
- <https://globalhealthtrainingcentre.tghn.org/ich-good-clinical-practice/>>

Hereby Certifies that
WIN AUNG
has completed the e-learning course
**ICH GOOD CLINICAL
PRACTICE E6 (R2)**

with a score of

100%

on

27/06/2018

This e-learning course has been formally recognised for its quality and content by the following organisations and institutions



This ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by TransCelerate BioPharma as necessary to enable mutual recognition of GCP training among trial sponsors.

Global Health Training Centre
globalhealthtrainingcentre.org/elearning

Certificate Number 436921



NIDA Clinical Trials Network

Certificate of Completion

is hereby granted to

Win Aung

to certify your completion of the six-hour required course on:

GOOD CLINICAL PRACTICES

MODULE:	STATUS:
Introduction	N/A
Institutional Review Boards	Passed
Informed Consent	Passed
Confidentiality & Privacy	Passed
Participant Safety & Adverse Events	Passed
Quality Assurance	Passed
The Research Protocol	Passed
Documentation & Record-Keeping	Passed
Research Misconduct	Passed
Roles & Responsibilities	Passed
Recruitment & Retention	Passed
Investigational New Drugs	Passed

Course Completion Date: 27 December 2017

CTN Expiration Date: 27 December 2020



Tracee Williams, Training Coordinator
NIDA Clinical Coordinating Center

This training has been funded in whole or in part with Federal funds from the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN07180101000014C.

Thank You

For Your Kind Attention !